会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 13. 发明申请
    • Novel Estrogenic Compounds
    • 新型雌激素化合物
    • US20100234330A1
    • 2010-09-16
    • US12788450
    • 2010-05-27
    • Edward N. HillFrederick D. SancilioRobert R. Whittle
    • Edward N. HillFrederick D. SancilioRobert R. Whittle
    • A61K31/56A61K31/59A61P5/24
    • C07J1/00C07J17/00
    • Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an α or a β orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.
    • 提供式I的新型雌激素化合物。 其中由波浪线表示的键可以是单键或双键,使得当波浪线为单键时,R 1选自氢,硫酸根和葡糖醛酸酯或其它酯,并且当波浪线为 双键,R1不存在; R2是低级烷基; R3可以选自氢,硫酸盐或葡糖苷酸或其他酯; R 4至R 13可以独立地选自氢,羟基,酮,低级烷基,低级烷氧基,卤素和羰基,R 14选自氢,硫酸根和葡萄糖醛酸和其它酯。 当R 1是羟基时,羟基或酯取代基可以具有α或a bgr; 方向。 还提供包括本发明化合物的物质组合物,其方法是使用本发明化合物治疗需要治疗的哺乳动物。
    • 14. 发明授权
    • Estrogenic compounds and topical pharmaceutical formulations of the same
    • 雌激素化合物和局部药物制剂相同
    • US07459445B2
    • 2008-12-02
    • US11671718
    • 2007-02-06
    • Edward N. HillFrederick D. SancilioRobert R. Whittle
    • Edward N. HillFrederick D. SancilioRobert R. Whittle
    • A61K31/56C07J1/00
    • C07J1/00C07J17/00
    • Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an α or a β orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.
    • 提供式I的新型雌激素化合物。 其中由波浪线表示的键可以是单键或双键,使得当波浪线为单键时,R 1选自氢,硫酸根和葡糖醛酸酯或其它酯,并且当波浪线为 双键,R1不存在; R2是低级烷基; R3可以选自氢,硫酸盐或葡糖苷酸或其他酯; R 4至R 13可以独立地选自氢,羟基,酮,低级烷基,低级烷氧基,卤素和羰基,R 14选自氢,硫酸根和葡萄糖醛酸和其它酯。 当R 1是羟基时,羟基或酯取代基可具有α或β取向。 还提供包括本发明化合物的物质组合物,其方法是使用本发明化合物治疗需要治疗的哺乳动物。
    • 18. 发明授权
    • Process for autoclaving molybdenum disulfide
    • 高温处理二硫化钼的方法
    • US5804151A
    • 1998-09-08
    • US931147
    • 1997-09-16
    • William H. SweetserLeonard N. Hill
    • William H. SweetserLeonard N. Hill
    • C01G39/02C01G37/14
    • C01G39/02C01P2006/80
    • A method for producing MoO.sub.3 from MoS.sub.2. MoS.sub.2 is combined with water to form a slurry which is then combined with at least one oxygen-containing oxidizing gas in a reaction chamber in order to initiate oxidization and conversion of MoS.sub.2 into MoO.sub.3. The oxidization and conversion of MoS.sub.2 into MoO.sub.3 is terminated before complete conversion of MoS.sub.2 to MoO.sub.3 takes place in order to generate a solid reaction product comprising MoO.sub.3 and unreacted MoS.sub.2 in combination with a residual liquid product comprising dissolved Mo therein. The oxidization and conversion process may be terminated when about 70-95% by weight MoS.sub.2 has been converted to MoO.sub.3. Thereafter, the solid reaction product is separated from the residual liquid product and the residual liquid product combined with at least one extractant in order to generate a liquid fraction containing dissolved Mo. The liquid fraction containing dissolved Mo is then transferred back to the reaction chamber so that the dissolved Mo is combined with additional incoming supplies of MoS.sub.2. Unreacted MoS.sub.2 is removed from the solid reaction product and transferred back to the reaction chamber also for combination with additional incoming supplies of MoS.sub.2.
    • 从MoS2制备MoO 3的方法。 MoS2与水结合形成浆料,然后与反应室中的至少一种含氧氧化气体结合,以便开始氧化并将MoS 2转化为MoO 3。 在MoS 2完全转化为MoO 3之前,MoS 2的氧化和转化被终止,以便产生包含MoO 3和未反应的MoS 2的固体反应产物与其中含有溶解的Mo的残余液体产物。 当约70-95重量%的MoS 2转化为MoO 3时,氧化和转化过程可以终止。 此后,将固体反应产物与剩余液体产物和残余液体产物与至少一种萃取剂组合分离,以产生含有溶解的Mo的液体馏分。然后将含有溶解的Mo的液体馏分转移回反应室 溶解的Mo与额外的进料MoS2组合。 从固体反应产物中除去未反应的MoS 2并转移回反应室,以与额外的进料MoS2组合。